Fc Region

Fc Region designates the fragment crystallisable portion of an antibody responsible for interacting with immune effector systems and extending antibody circulation time through neonatal Fc receptor recycling. This region mediates functions including antibody-dependent cellular cytotoxicity, complement activation, and binding to Fc receptors on immune cells, making it critical for therapeutic antibody performance beyond simple antigen recognition.

The biopharmaceutical industry optimises Fc regions through protein engineering to tune immune activity, extend half-life, or reduce unwanted effector functions depending on therapeutic intent. Fc engineering strategies include modifying glycosylation patterns, introducing amino acid substitutions enhancing Fc receptor binding, or reducing complement activation to improve safety. Manufacturing must ensure consistent Fc glycan profiles, as Fc glycosylation directly affects effector potency. Regulatory submissions include Fc characterisation demonstrating structural integrity and functional performance across batches. As antibody formats diversify into bispecifics and engineered constructs, Fc region design remains central to maximising efficacy while maintaining acceptable safety profiles.